NEO
NeoGenomics, Inc. · Healthcare
Insiders sold $968K of NeoGenomics, Inc. in the last 12 months and bought none
NEO over the last year
NEO after insider buys
3 months after each buy, from the first price a copier could get.
7 buys since 2016 with 3 months of prices.
Congress
Members reported 2 trades in NEO since 2025.
Every filing
103 insider filings since 2016, newest first
George Cardoza · Pres, Pharma Services
Robert J. Shovlin · Pres, Clinical Services
Steven C Jones · Director
William Bonello · Chief Strategy Officer
Steven C Jones · Director
Raymond R Hipp · Director
Kevin C Johnson · Director
Steven C Jones · Director
Raymond R Hipp · Director
William Bonello · Chief Strategy Officer
George Cardoza · Pres, Pharma Services
Jennifer Balliet · VP and Chief Culture Officer
Robert J. Shovlin · Pres, Clinical Services
Jennifer Balliet · VP and Chief Culture Officer
Steven C Jones · EVP
Robert J. Shovlin · Pres, Clinical Services
William Bonello · Chief Strategy Officer
Raymond R Hipp · Director
Kevin C Johnson · Director
Electric Co General · Former 10% Owner
Lynn A. Tetrault · Director
Lynn A. Tetrault · Director
Steven C Jones · EVP
Electric Co General · 10% owner
Kevin C Johnson · Director
Robert J. Shovlin · Pres, Clinical Services
Jennifer Balliet · VP and Chief Culture Officer
Steven C Jones · EVP
Robert J. Shovlin · Pres, Clinical Services
Steven C Jones · EVP
Steven C Jones · EVP
Steven C Jones · EVP
Steven C Jones · EVP
Jennifer Balliet · VP and Chief Culture Officer
Jennifer Balliet · VP and Chief Culture Officer
Steven A Ross · CIO
Alison L. Hannah · Director
Jennifer Balliet · VP and Chief Culture Officer
Steven A Ross · CIO
Jennifer Balliet · VP and Chief Culture Officer
Steven G. Brodie · Pres, Pharma Services
Maher Albitar · Chief Medical Officer
Maher Albitar · Chief Medical Officer
Maher Albitar · Chief Medical Officer
Oort Douglas M Van · Chair and CEO
Steven A Ross · CIO
Steven A Ross · CIO
Steven C Jones · EVP of Finance
Steven A Ross · CIO
George Cardoza · CFO
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.